Celcuity (CELC)
Nasdaq Market Closed
Celcuity Inc. is a clinical-stage biotechnology company focused on targeted cancer treatments for patients with solid tumors. Its work centers on understanding and inhibiting signaling pathways that drive tumor growth, with a particular emphasis on hormone receptor-positive, HER2-negative breast cancer, one of the most common breast cancer subtypes.
The company’s lead drug candidate is gedatolisib, an investigational therapy designed to inhibit the PI3K/AKT/mTOR, or PAM, pathway. This pathway is frequently implicated in cancer cell growth, survival, and resistance to endocrine therapy. Gedatolisib is differentiated by its approach to pathway inhibition: it targets all class I PI3K isoforms as well as both mTORC1 and mTORC2, creating a broader mechanism than therapies aimed at a single component of the pathway.
Celcuity is evaluating gedatolisib in several clinical programs. Its Phase 3 VIKTORIA-1 trial studies gedatolisib in combination with fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative advanced breast cancer after prior endocrine therapy. The trial has completed enrollment and has reported results for patients with PIK3CA wild-type tumors, while its PIK3CA-mutant cohort has also enrolled.
The company is also advancing VIKTORIA-2, another Phase 3 study in endocrine-resistant HR-positive, HER2-negative breast cancer, and CELC-G-201, a Phase 1b/2 trial exploring gedatolisib combinations in metastatic castration-resistant prostate cancer. As a development-stage biotech, Celcuity’s value is closely tied to clinical outcomes, regulatory progress, and the potential commercial role of gedatolisib in oncology treatment.
Last updated
- Market Cap
- 4.34B
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- 4.52B
- Sector
- Health Care
- Industry
- Medical Laboratories
- Address
- 16305 36TH AVENUE N, MINNEAPOLIS, MN, 55446
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
Celcuity To Participate in Jefferies Global Healthcare Conference
Celcuity Announces Pricing of Underwritten Common Stock Offering
Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Why Celcuity (CELC) Might Surprise This Earnings Season
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 4.34B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 4.52B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 81.04
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -24.23
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -3.96
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -172.93M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -360.37%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -47.03%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 6.04
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 12.31
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 12.31
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 4.37
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 1.46M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 88.95
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -50.51M | -49.2M | -42.85M | -44.01M | -36.13M |
| EBITDA | -50.46M | -49.15M | -42.81M | -43.97M | -36.1M |
| Net income | -52.84M | -50.97M | -43.8M | -45.27M | -37M |
| Basic EPS | -0.97 | -0.98 | -0.92 | -1.04 | -0.86 |
| Diluted EPS | -0.97 | -0.98 | -0.92 | -1.04 | -0.86 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 410.16M | 466.56M | 476M | 183.59M | 218.13M |
| Total liabilities | 356.64M | 366M | 359.04M | 139.22M | 131.46M |
| Total equity | 53.53M | 100.56M | 116.96M | 44.38M | 86.67M |
| Cash & equivalents | 145.19M | 165.7M | 74.25M | 46.35M | 16.48M |
| Current assets | 408.93M | 465.66M | 475.5M | 183.1M | 217.6M |
| Current liabilities | 33.21M | 44.15M | 38.79M | 39.94M | 32.92M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -55.07M | -36.4M | -44.82M | -36.21M | -35.85M |
| Investing cash flow | 34.52M | 103.41M | -257.61M | 65.86M | 24.26M |
| Financing cash flow | 34K | 24.44M | 330.33M | 232K | 5.55M |
| Change in cash | -20.51M | 91.45M | 27.9M | 29.88M | -6.04M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 424B5 — Celcuity Inc. | View Filing | |
| edgar index | 8-K — Celcuity Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K/A — Celcuity Inc. | View Filing | |
| edgar index | 4 — Celcuity Inc. | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| edgar index | 8-K — Celcuity Inc. | View Filing | |
| edgar index | S-8 — Celcuity Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — Celcuity Inc. | View Filing | |
| edgar index | 8-K — Celcuity Inc. | View Filing | |
| edgar index | 10-Q — Celcuity Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Celcuity Inc. | View Filing | |
| edgar index | 4 — Celcuity Inc. | View Filing | |
| edgar index | 144 — Celcuity Inc. | View Filing | |
| edgar index | 144 — Celcuity Inc. | View Filing | |
| form 4 | Form 4 — Dalvey David | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| edgar index | 8-K — Celcuity Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Celcuity Inc. | View Filing | |
| form 4 | Form 4 — NIGON RICHARD | View Filing | |
| edgar index | DEF 14A — Celcuity Inc. | View Filing | |
| edgar index | DEFA14A — Celcuity Inc. | View Filing | |
| edgar index | ARS — Celcuity Inc. | View Filing | |
| edgar index | 4 — Celcuity Inc. | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| edgar index | 10-K — Celcuity Inc. | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — Celcuity Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13D/A — Celcuity Inc. | View Filing | |
| edgar index | SCHEDULE 13D/A — Celcuity Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Celcuity Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Celcuity Inc. | View Filing | |
| edgar index | 3 — Celcuity Inc. | View Filing | |
| edgar index | 4 — Celcuity Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Celcuity Inc. | View Filing | |
| edgar index | 8-K — Celcuity Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — ROMP CHARLES R | View Filing | |
| edgar index | 4 — Celcuity Inc. | View Filing | |
| edgar index | 144 — Celcuity Inc. | View Filing | |
| form 4 | Form 4 — Dalvey David | View Filing | |
| edgar index | SCHEDULE 13D/A — Celcuity Inc. | View Filing | |
| edgar index | 4 — Celcuity Inc. | View Filing | |
| edgar index | S-3ASR — Celcuity Inc. | View Filing | |
| form 4 | Form 4 — NIGON RICHARD | View Filing | |
| edgar index | 4 — Celcuity Inc. | View Filing | |
| edgar index | 4 — Celcuity Inc. | View Filing | |
| edgar index | 144 — Celcuity Inc. | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Buller Richard E | View Filing | |
| form 4 | Form 4 — Furcht Leo | View Filing | |
| form 4 | Form 4 — Furcht Leo | View Filing | |
| edgar index | 4 — Celcuity Inc. | View Filing |